- PO (Adults): 45 mg/m2/day in 2 divided doses; treatment should be continued for 30 days after a complete remission has been achieved or for a total of 90 days, whichever is first.
Contraindicated in:
Use Cautiously in:
EENT: altered visual acuity, ocular disorders, visual disturbances, visual field defects, earache, hearing loss.
Resp: asthma, laryngeal edema.
CV: CARDIAC FAILURE, MI, STROKE, arrhythmias, chest discomfort, edema, hypertension, hypotension, peripheral edema, phlebitis.
GI: GI BLEEDING, abdominal distention, abdominal pain, anorexia, constipation, diarrhea, dry mouth, dyspepsia, hepatosplenomegaly, mucositis, nausea, ulcer, vomiting.
GU: renal insufficiency, acute renal failure, dysuria, enlarged prostate, renal tubular necrosis, urinary frequency.
Derm: alopecia, cellulitis, dry skin, facial edema, flushing, ↑ sweating, pallor, pruritus, rash, skin changes.
F and E: acidosis, fluid imbalance.
Hemat: disseminated intravascular coagulation, hemorrhage, leukocytosis.
Metab: weight gain, weight loss.
MS: bone inflammation, bone pain, flank pain, myalgia.
Neuro: paresthesias, SEIZURES, anxiety, confusion, depression, dizziness, fatigue, headache, insomnia, malaise, pseudotumor cerebri, weakness, agitation, cerebral hemorrhage, hallucinations, intracranial hypertension.
Misc: fever, infections, pain, hypothermia, retinoic acid–acute promyelocytic leukemia syndrome, shivering.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Absorption: Well absorbed following oral administration.
Distribution: Crosses the placenta; remainder of distribution unknown.
Protein Binding: >95%.
Metabolism/Excretion: Metabolized by the liver; metabolites are renally excreted.
Half-life: 0.5–2 hr.
NDC Code*